Molecular Medicine

, Volume 18, Issue 3, pp 401–411 | Cite as

Human Skeletal Muscle Stem Cell Antiinflammatory Activity Ameliorates Clinical Outcome in Amyotrophic Lateral Sclerosis Models

  • Laura Canzi
  • Valeria Castellaneta
  • Stefania Navone
  • Sara Nava
  • Marta Dossena
  • Ileana Zucca
  • Tiziana Mennini
  • Paolo Bigini
  • Eugenio A Parati
Research Article


Mesenchymal stem cell (MSC) therapy is considered one of the most promising approaches for treating different neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS). We previously characterized a subpopulation of human skeletal muscle-derived stem cells (SkmSCs) with MSC-like characteristics that differentiate into the neurogenic lineage in vitro. In the present study, we evaluated the SkmSC therapeutic effects in the most characterized model of spontaneous motor neuron degeneration, the Wobbler (Wr) mouse. Before evaluating the therapeutic efficacy in the Wr mouse, we followed the route of SkmSCs at different times after intracerebroventricular injection. Two exogenous tracers, superparamagnetic iron oxide (SPIO) nanoparticles and Hoechst 33258, were used for the in vivo and ex vivo tracking of SkmSCs. We found that the loading of both Hoechst and SPIO was not toxic and efficiently labeled SkmSCs. The magnetic resonance imaging (MRI) system 7 Tesla allowed us to localize transplanted SkmSCs along the whole ventricular system up to 18 wks after injection. The ex vivo Hoechst 33258 visualization confirmed the in vivo results obtained by MRI analyses. Behavioral observations revealed a fast and sustained improvement of motor efficacy in SkmSC-treated Wr mice associated with a relevant protection of functional neuromuscular junctions. Moreover, we found that in SkmSC-treated Wr mice, a significant increase of important human antiinflammatory cytokines occurred. This evidence is in accordance with previous findings showing the bystander effect of stem cell transplantation in neurodegenerative disorders and further strengthens the hypothesis of the possible link between inflammation, cytotoxicity and ALS.



We are grateful to Andrea Smith for the helpful review of the English in the manuscript. We also thank Giulio Alessandri and Giorgio Battaglia for critically reading this scientific article. This work was supported by IRCCS Foundation Neurological Institute “C. Besta” (LR8) and by the Italian Ministry of Health (RF-INN-2007-644440).

Supplementary material

10020_2012_1803401_MOESM1_ESM.pdf (499 kb)
Human Skeletal Muscle Stem Cell Antiinflammatory Activity Ameliorates Clinical Outcome in Amyotrophic Lateral Sclerosis Models


  1. 1.
    Boillee S, Cleveland DW. (2008) Revisiting oxidative damage in ALS: microglia, Nox, and mutant SOD1. J. Clin. Invest. 118:474–8.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Wokke J. (1996) Riluzole. Lancet. 348:795–9.CrossRefGoogle Scholar
  3. 3.
    Lodi D, Iannitti T, Palmieri B. Stem cells in clinical practice: applications and warnings. J. Exp. Clin. Cancer Res. 30:9.CrossRefGoogle Scholar
  4. 4.
    Justesen J, Stenderup K, Eriksen EF, Kassem M. (2002) Maintenance of osteoblastic and adipocytic differentiation potential with age and osteoporosis in human marrow stromal cell cultures. Calcif. Tissue Int. 71:36–44.CrossRefGoogle Scholar
  5. 5.
    Jiang Y, et al. (2002) Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 418:41–9.CrossRefGoogle Scholar
  6. 6.
    Sanchez-Ramos J, et al. (2000) Adult bone marrow stromal cells differentiate into neural cells in vitro. Exp. Neurol. 164:247–56.CrossRefGoogle Scholar
  7. 7.
    Alessandri G, et al. (2004) Isolation and culture of human muscle-derived stem cells able to differentiate into myogenic and neurogenic cell lineages. Lancet. 364:1872–83.CrossRefGoogle Scholar
  8. 8.
    Gotherstrom C, et al. (2004) Immunologic properties of human fetal mesenchymal stem cells. Am. J. Obstet. Gynecol. 190:239–45.CrossRefGoogle Scholar
  9. 9.
    Garbuzova-Davis S, et al. (2008) Human umbilical cord blood treatment in a mouse model of ALS: optimization of cell dose. PLoS One. 3:e2494.CrossRefGoogle Scholar
  10. 10.
    Falconer DS. (1956). Mouse News Letter. 15:23.Google Scholar
  11. 11.
    Schmitt-John T, et al. (2005) Mutation of Vps54 causes motor neuron disease and defective spermiogenesis in the wobbler mouse. Nat. Genet. 37:1213–5.CrossRefGoogle Scholar
  12. 12.
    Fumagalli E, Bigini P, Barbera S, De Paola M, Mennini T. (2006) Riluzole, unlike the AMPA antagonist RPR119990, reduces motor impairment and partially prevents motoneuron death in the wobbler mouse, a model of neurodegenerative disease. Exp. Neurol. 198:114–28.CrossRefGoogle Scholar
  13. 13.
    Palmisano R, et al. (2011) Endosomal accumulation of APP in wobbler motor neurons reflects impaired vesicle trafficking: implications for human motor neuron disease. BMC Neurosci. 12:24.CrossRefGoogle Scholar
  14. 14.
    Wada MR, Inagawa-Ogashiwa M, Shimizu S, Yasumoto S, Hashimoto N. (2002) Generation of different fates from multipotent muscle stem cells. Development. 129:2987–95.PubMedGoogle Scholar
  15. 15.
    Neri M, et al. (2008) Efficient in vitro labeling of human neural precursor cells with superparamagnetic iron oxide particles: relevance for in vivo cell tracking. Stem Cells. 26:505–16.CrossRefGoogle Scholar
  16. 16.
    D.L. no. 116, G.U. suppl. 40, 18 February 1992.Google Scholar
  17. 17.
    Circolare no. 8, G.U., 14 Luglio 1994.Google Scholar
  18. 18.
    EEC Council Directive 86/609, OJ L 358, 1, Dec. 12, 1987.Google Scholar
  19. 19.
    Institute of Laboratory Animal Resources; Commission on Life Sciences; National Research Council. (1996) Guide for the Care and Use of Laboratory Animals. Washington (DC): National Academy Press. Available from: Scholar
  20. 20.
    Rathke-Hartlieb S, Schmidt VC, Jockusch H, Schmitt-John T, Bartsch JW. (1999) Spatiotemporal progression of neurodegeneration and glia activation in the wobbler neuropathy of the mouse. Neuroreport. 10:3411–6.CrossRefGoogle Scholar
  21. 21.
    Mennini T, et al. (2006) Nonhematopoietic erythropoietin derivatives prevent motoneuron degeneration in vitro and in vivo. Mol. Med. 12:153–60.CrossRefGoogle Scholar
  22. 22.
    Bigini P, Mennini T. (2004) Immunohistochemical localization of TNFalpha and its receptors in the rodent central nervous system. Methods Mol. Med. 98:73–80.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Bigini P, et al. (2010) Neuropathologic and biochemical changes during disease progression in liver X receptor beta-/- mice, a model of adult neuron disease. J. Neuropathol. Exp. Neurol. 69:593–605.CrossRefGoogle Scholar
  24. 24.
    Dominici M, et al. (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 8:315–7.CrossRefGoogle Scholar
  25. 25.
    Yin AH, et al. (1997) AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90:5002–12.PubMedGoogle Scholar
  26. 26.
    Ogawa Y, et al. (2002) Transplantation of in vitroexpanded fetal neural progenitor cells results in neurogenesis and functional recovery after spinal cord contusion injury in adult rats. J. Neurosci. Res 69:925–33.CrossRefGoogle Scholar
  27. 27.
    Cristofanilli M, Harris VK, Zigelbaum A, et al. (2011) Mesenchymal stem cells enhance the engraftment and myelinating ability of allogeneic oligodendrocyte progenitors in dysmyelinated mice. Stem Cells Dev. 20:2065–76.CrossRefGoogle Scholar
  28. 28.
    Mazzini L, et al. (2010) Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: a phase I clinical trial. Exp. Neurol. 223:229–37.CrossRefGoogle Scholar
  29. 29.
    Rehni AK, Singh N, Jaggi AS, Singh M. (2007) Amniotic fluid derived stem cells ameliorate focal cerebral ischaemia-reperfusion injury induced behavioural deficits in mice. Behav. Brain Res. 183:95–100.CrossRefGoogle Scholar
  30. 30.
    Benatar M. (2007) Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol. Dis. 26:1–13.CrossRefGoogle Scholar
  31. 31.
    Keep M, Elmer E, Fong KS, Csiszar K. (2001) Intrathecal cyclosporin prolongs survival of latestage ALS mice. Brain Res. 894:327–31.CrossRefGoogle Scholar
  32. 32.
    Mosley RL, Gendelman HE. Control of neuroinflammation as a therapeutic strategy for amyotrophic lateral sclerosis and other neurodegenerative disorders. Exp. Neurol. 222:1–5.CrossRefGoogle Scholar
  33. 33.
    Opal SM, Keith JC, Palardy JE, Parejo N. (2000) Recombinant human interleukin-11 has antiinflammatory actions yet does not exacerbate systemic Listeria infection. J. Infect. Dis. 181:754–6.CrossRefGoogle Scholar
  34. 34.
    Hoffmann KF, Cheever AW, Wynn TA. (2000) IL-10 and the dangers of immune polarization: excessive type 1 and type 2 cytokine responses induce distinct forms of lethal immunopathology in murine schistosomiasis. J. Immunol. 164:6406–16.CrossRefGoogle Scholar
  35. 35.
    Qiu F, et al. (2006) [Effect of ligustrazine on cell proliferation in subventricular zone of lateral cerebral ventricle after adult rat suffering from focal cerebral ischemia]. Sichuan Da Xue Xue Bao Yi Xue Ban 37:726–9, 780.PubMedGoogle Scholar
  36. 36.
    Bigini P, et al. (2007) Lack of caspase-dependent apoptosis in spinal motor neurons of the wobbler mouse. Neurosci. Lett. 426:106–10.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2012

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (

Authors and Affiliations

  • Laura Canzi
    • 1
    • 2
  • Valeria Castellaneta
    • 3
  • Stefania Navone
    • 1
  • Sara Nava
    • 1
  • Marta Dossena
    • 1
  • Ileana Zucca
    • 4
  • Tiziana Mennini
    • 3
  • Paolo Bigini
    • 3
  • Eugenio A Parati
    • 1
  1. 1.Department of Cerebrovascular DiseaseIRCCS Foundation, Neurological Institute “C. Besta”MilanItaly
  2. 2.Department of Biotechnology and BiosciencesUniversity of Milano-BicoccaMilanItaly
  3. 3.Department of Molecular Biochemistry and PharmacologyMario Negri Institute for Pharmacological ResearchMilanItaly
  4. 4.Science Direction UnitIRCCS Foundation, Neurological Institute “C. Besta”MilanItaly

Personalised recommendations